original Cox models: the ¹³¹I-treated cohort did not have a significantly greater risk of breast cancer (hazard ratio, 1.07; 95% confidence ratio, 0.73–1.57) than the nontreated cohort. Table 2 of our article presented the full data.

Chun-Yi Lin Cheng-Li Lin Chia-Hung Kao* *China Medical University 2 Yuh-Der Rd. Taichung 404, Taiwan E-mail: d10040@mail.cmuh.org.tw

REFERENCE

 Lin CY, Lin CL, Huang WS, Kao CH. Risk of breast cancer in patients with thyroid cancer receiving or not receiving ¹³¹I treatment: a nationwide populationbased cohort study. *J Nucl Med.* 2015;57:685–690.

Published online May 19, 2016. DOI: 10.2967/jnumed.116.178152

Errata

In the article "Evaluation of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy," by Eiber et al. (*J Nucl Med.* 2015;56:668–674), the last name of one of the authors was misspelled. "Uwe Haberhorn" should be "Uwe Haberkorn." The authors regret the error.

In the article "¹⁸F-FDG PET/CT Is an Immediate Imaging Biomarker of Treatment Success After Liver Metastasis Ablation," by Cornelis et al. (*J Nucl Med.* 2016;57:1052–1057), the last name of one of the authors was misspelled. "Vlasios Storchios" should be "Vlasios Sotirchos." We regret the error.